Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028860 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer
A Phase 2 study, sponsored by Tulane University Health Sciences Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00028860 is a Phase 2 study that has completed, run by Tulane University Health Sciences Center.
The verdict
NCT00028860, a Phase 2 study, has completed, sponsored by Tulane University Health Sciences Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients who have urinary tract cancer.
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- DRUG ifosfamide
- BIOLOGICAL filgrastim
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-10 |
| Est. Completion | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028860
The ClinicalTrials.gov registry entry for NCT00028860 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Tulane University Health Sciences Center, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00028860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028860 about?
NCT00028860 is a clinical study titled "Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following surgery in treating patients who h...
What is the current status of trial NCT00028860?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-10. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00028860?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), ifosfamide (DRUG), filgrastim (BIOLOGICAL), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00028860?
This trial is sponsored by Tulane University Health Sciences Center, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.